💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for CD

No earnings history available for this symbol.

📰 Related News & Research

• CDL Hospitality Trusts to Release Q1 2026 Operational Update on 30 April 2026 1
  March 27, 2026
  

  CDL Hospitality Trusts: Q1 2026 Operational Update Announcem...

• SeaStar Medical Holding Corp 2025 Annual Report: SCD Therapy for Acute Kidney Injury, Market Opportunities, and Intellectual Property Portfolio
  March 26, 2026
  

  SeaStar Medical Holding Corporation Releases Annual Report: ...

• Sealed Air Receives Regulatory Approvals for CD&R Acquisition, Set to Go Private in April 202
  March 23, 2026
  

  Sealed Air Corporation Receives Final Regulatory Approvals f...

• Gyre Therapeutics Submits NDA for F351 (Hydronidone) to China CDE for Treatment of Chronic Hepatitis B-Induced Liver Fibrosis
  March 23, 2026
  

  Gyre Therapeutics Files New Drug Application for F351 (Hydro...

• Nuveen Churchill Direct Lending Corp. (NCDL) 8-K SEC Filing Highlights: Company Details, Address, and Stock Information
  March 20, 2026
  

  Nuveen Churchill Direct Lending Corp. Announces \$50 Million...

• CDT Equity Inc. 8-K Filing March 17, 2026: Company Details, Address, Trading Symbol, and Emerging Growth Status
  March 19, 2026
  

  CDT Equity Inc. Special Shareholder Meeting Results - Detail...

• Lifecore Biomedical Targets 12% Revenue CAGR and 25%+ EBITDA Margin by 2029 with CDMO Growth Strategy
  March 16, 2026
  

  Lifecore Biomedical, Inc. Issues Strategic Update: New Fisca...

• Lifecore Biomedical Expands CDMO Capabilities with New Aseptic Filler and Strategic Growth Initiatives
  March 16, 2026
  

  Lifecore Biomedical, Inc. 10-KT Transition Report: Key Inves...

• ProFrac Holding Corp. (ACDC) 2025 Annual Report: Financials, Risk Factors, and SEC Filing Details
  March 14, 2026
  

  ProFrac Holding Corp. (ACDC) 2025 Annual Report: Key Insight...

• Alphamab Oncology’s JSKN021 IND Application Accepted by China CDE for Advanced Solid Tumors – Phase I Trial Planned
  March 13, 2026
  

  Alphamab Oncology: IND Application for JSKN021 Accepted by C...

🔍 View more Reports